Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants
Sponsored by AbbVie
About this trial
Last updated a year ago
Study ID
M23-889
Status
Completed
Type
Interventional
Phase
Phase 1
Placebo
Yes
Accepting
18 to 65 Years
All
Trial Timing
Ended a year ago
What is this trial about?
The main objective of this study is to assess pharmacokinetics, safety, and tolerability
of ABBV-932 in healthy adult participants.
What are the participation requirements?
Inclusion Criteria
- Parts 1 and 2: Healthy individuals with body-mass index (BMI) >= 18.0 to <= 32.0 kg/m2, rounded to the tenths decimal.
- Part 3: Healthy Japanese, Han Chinese individuals with BMI >= 18.0 to <= 30.0 kg/m2, rounded to the tenths decimal.
- Condition of general good health based upon the results of a medical history, physical examination, vital signs, laboratory profile, neurological examination, and a 12-lead ECG.
Exclusion Criteria
- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
For more information, view the full study details:
NCT05738850